Paul Bisaro Buys 2,000 Shares of Zoetis (NYSE:ZTS) Stock

Zoetis Inc. (NYSE:ZTS) Director Paul Bisaro acquired 2,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Zoetis Stock Up 1.7%

Shares of Zoetis stock opened at $75.57 on Friday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The firm has a market cap of $31.68 billion, a P/E ratio of 12.53, a P/E/G ratio of 1.21 and a beta of 0.87. Zoetis Inc. has a fifty-two week low of $73.98 and a fifty-two week high of $172.23. The business has a 50-day moving average price of $113.32 and a 200 day moving average price of $121.27.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ZTS has been the subject of several research analyst reports. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Piper Sandler reissued a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. UBS Group lowered their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Finally, Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $141.25.

Hedge Funds Weigh In On Zoetis

Institutional investors have recently made changes to their positions in the stock. Global Wealth Strategies & Associates bought a new position in shares of Zoetis during the fourth quarter valued at approximately $25,000. Prosperity Bancshares Inc bought a new position in shares of Zoetis during the fourth quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp bought a new position in shares of Zoetis during the third quarter valued at approximately $31,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Zoetis during the first quarter valued at approximately $28,000. Finally, Lodestone Wealth Management LLC bought a new position in shares of Zoetis during the fourth quarter valued at approximately $30,000. 92.80% of the stock is owned by institutional investors.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.